Equities research analysts at Cantor Fitzgerald decreased their FY2025 earnings estimates for Biogen in a research note ...

Biogen (NASDAQ:BIIB – Get Free Report)‘s stock had its “hold” rating reiterated by equities research analysts at Needham & ...

Biosimilar adalimumab is backed by robust science ... Amgen (Amgevita and Solymbi), Boehringer Ingelheim (Cyltezo), Samsung Bioepis (Imraldi) will be key, with health systems keen to benefit ...

Smith and Winter’s work on a technique known as phage display was notably used to develop Humira (adalimumab), first approved in 2002 and now used in a range of inflammatory diseases.

After hours: 7:52:17 p.m. EST ...

Objective CONCERTO was a randomised, double-blind, parallel-armed study of methotrexate (MTX) in combination with adalimumab to assess whether an increasing trend of efficacy and decreased safety ...

Pre-market: 4:26:51 am GMT-5 ...